机译:预处理中性粒细胞淋巴细胞和血小板淋巴细胞比率预测宫颈癌的临床结果和预后
Chengdu Med Coll Dept Med Imaging Chengdu 610500 Sichuan Peoples R China;
Sichuan Univ West China Univ Hosp 2 Dept Pathol Chengdu 610041 Sichuan Peoples R China;
Chengdu Med Coll Dept Med Imaging Chengdu 610500 Sichuan Peoples R China;
Chengdu Med Coll Dept Med Imaging Chengdu 610500 Sichuan Peoples R China;
Chengdu Med Coll Dept Med Imaging Chengdu 610500 Sichuan Peoples R China;
Chengdu Med Coll Dept Med Imaging Chengdu 610500 Sichuan Peoples R China;
Second Peoples Hosp Chengdu Dept Gen Surg Dept Breast &
Vasc Surg Chengdu 610017 Sichuan;
Chengdu Med Coll Dept Pathol &
Pathophysiol Chengdu 610500 Sichuan Peoples R China;
Chengdu Med Coll Dept Pathol &
Pathophysiol Chengdu 610500 Sichuan Peoples R China;
Chengdu Med Coll Dept Pathol &
Pathophysiol Chengdu 610500 Sichuan Peoples R China;
Chengdu Med Coll Dept Pathol &
Pathophysiol Chengdu 610500 Sichuan Peoples R China;
Chengdu Med Coll Dept Pathol &
Pathophysiol Chengdu 610500 Sichuan Peoples R China;
Chengdu Med Coll Dept Pathol &
Pathophysiol Chengdu 610500 Sichuan Peoples R China;
Cervical cancer; NLR; PLR; Predict markers; Parametrial involvement; Prognosis;
机译:预处理中性粒细胞淋巴细胞和血小板淋巴细胞比率预测宫颈癌的临床结果和预后
机译:术前中性粒细胞-淋巴细胞比和血小板-淋巴细胞比在临床上不能用于预测早期宫颈癌的预后
机译:术前中性粒细胞-淋巴细胞比值先于血小板-淋巴细胞比值预测初始根治性手术治疗宫颈癌患者的临床结局
机译:癌症生物学在癌症分期和预测临床结果中的应用
机译:临床前癌症模型的临床预测价值:体外细胞系,人异种移植和小鼠同种异体移植临床前癌症模型对细胞毒性癌症药物II期临床试验的预测价值研究
机译:术前中性粒细胞-淋巴细胞比和血小板-淋巴细胞比在临床上不能用于预测早期宫颈癌的预后
机译:组合中性粒细胞淋巴细胞比和血小板淋巴细胞比率预测晚期胃癌患者的化疗响应和预后